INCYTE
18424
357 |
The purpose of the RELIEF study is to compare symptoms in polycythemia vera (PV) subjects treated with ruxolitinib versus subjects treated with hydroxyurea (HU) as measured by the percent of subjects who achieve a clinically meaningful symptom improvement (ie, total symptom score reduction of = 50% reduction) at Week 16 compared to Baseline. The study is also designed to demonstrate that these responses are durable with continued treatment.
Learn more.
|
NCT01632904 |
Merck
Vaccine
V212 |
A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy
Learn more.
|
NCT01254630 |
Prometheus
Proclaim
10PLK 13 |
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Learn more.
|
NCT01415167 |
Novartis
CRAD001T2302
SLHN 2012- 41 |
A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin - The Radiant 4
Learn more.
|
NCT01524783 |